- And a recipe for primary care #burnout which goes against all the #staff #wellbeing learning made during #COVID19… twitter.com/i/web/status/1… 1 day ago
- When male or female #sex no longer means anything, we have lost an anchor of #identity, a foundation of #certainty,… twitter.com/i/web/status/1… 3 days ago
- Were you watching @LisaSaysThis ?! twitter.com/philipmould/st… 6 days ago
Tag Archives: NICE
Guest Blog from the Mental Health Foundation The Select Committee on Health’s enquiry into children and young people’s mental health and the launch of the NHS England Mental Health Task Force are welcome developments in a year that has seen … Continue reading
2020Health claims legal enforcement of key measures are necessary to ensure ‘parity of esteem’ and for Britain to tackle depression in the workplace. 2020Health has today published a new report, ‘Whole in One – Achieving equality of status, access and resources … Continue reading
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
With opposition to the Health and Social Care Bill having reached new heights, we must look behind the rhetoric and remember basic principles. The most important point to remember is that the NHS exists to provide the best possible, affordable … Continue reading